ChatBot keeps tabs on cancer patients, could cut hospital trips

NCT ID NCT05318027

Ongoing Symptom relief Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a chatbot that texts patients and tracks their phone activity can catch cancer treatment symptoms early. About 70 adults with lung, gastrointestinal, or head and neck cancers will use the chatbot during chemo and radiation. The goal is to see if this approach reduces urgent clinic visits and hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ChatBot and activity monitoring via mobile phone
What this could lead to: If it works, this could help cancer patients manage treatment side effects at home and avoid unnecessary hospital visits.
What could go wrong: This is a small Phase 2 trial with only 70 people, so results may not apply to everyone. The chatbot may miss some symptoms or cause extra worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL CANCER HEAD AND NECK CANCER LUNG CANCER

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.